Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

CEL SCI CORP (CVM) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/20/2023 8-K Quarterly results
07/18/2023 8-K Quarterly results
07/14/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CEL-SCI CONCLUDES POSITIVE MEETING WITH U.S. FDA CONCERNING MULTIKINE’S APPROVAL FOR HEAD & NECK CANCER"
07/12/2023 8-K Quarterly results
05/23/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/02/2023 8-K Quarterly results
05/01/2023 8-K Quarterly results
04/19/2023 8-K Quarterly results
03/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension"
09/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CEL-SCI’S PHASE 3 DATA PRESENTED AT ESMO 2022: NEOADJUVANT MULTIKINE ACHIEVED GROUNDBREAKING TUMOR RESPONSE & EXTENDED OVERALL SURVIVAL IN LOCALLY ADVANCED HEAD AND NECK CANCER"
08/22/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
07/07/2021 8-K Quarterly results
07/01/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/29/2021 8-K Quarterly results
06/28/2021 8-K Quarterly results
06/09/2021 8-K Quarterly results
12/29/2020 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
12/09/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT",
"CONSENT OF HART & HART, LLC",
"OPINION OF HART & HART, LLC",
"CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, December 8, 2020 -- CEL-SCI Corporation , a Phase 3 cancer immunotherapy company, today announced that it has entered into an underwriting agreement with Kingswood Capital Markets, division of Benchmark Investments, Inc. and Aegis Capital Corp. under which the underwriters have agreed to purchase on a firm commitment basis a minimum of 1,000,000 shares of common stock of the Company, at a price to the public of $14.65 per share , representing a 5% discount to the Company’s December 8, 2020 closing share price. The closing of the offering is expected to occur on or about December 11, 2020, subject to customary closing conditions. Kingswood Capital Markets, division of Benchmark Investments, Inc. and Aegis Capital Corp. are acting as the joi..."
10/30/2020 8-K Material Modifications to Rights of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "SHAREHOLDER RIGHTS AGREEMENT"
07/01/2020 8-K Unregistered Sales of Equity Securities
05/26/2020 8-K Material Modifications to Rights of Security Holders, Financial Statements and Exhibits
Docs: "SERIES XX WARRANT",
"SERIES YY WARRANT"
04/17/2020 8-K Submission of Matters to a Vote of Security Holders
03/24/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Amended and Restated Underwriting Agreement, by and between CEL-SCI Corporation and Aegis Capital Corp",
"OPINION OF HART & HART, LLC",
"CONSENT OF HART & HART, LLC",
"CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, March 23, 2020 -- CEL-SCI Corporation , a Phase 3 cancer immunotherapy company, today announced today that it has entered into an underwriting agreement with Aegis Capital Corp. under which the underwriter has agreed to purchase on a firm commitment basis a minimum of 500,000 shares of common stock of the Company, at a price to the public of $12.22 per share , representing a 5% discount to the closing price per share. The closing of the offering is expected to occur on or about March 26, 2020, subject to customary closing conditions. Aegis Capital Corp. is acting as the sole book-running manager for the offering. The Company also has granted to the underwriter a 45-day option to purchase up to 15% of the offering at the Public Price. The u...",
"CEL-SCI INCREASES PREVIOUSLY ANNOUNCED BOUGHT DEAL TO $7.7 MILLION"
02/20/2020 8-K Quarterly results
12/26/2019 8-K Quarterly results
12/23/2019 8-K Quarterly results
10/15/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY Vienna, VA, October 15 , 2019 -- CEL-SCI Corporation announced today that the Independent Data Monitoring Committee for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* has completed its recent review of the Phase 3 study data. The IDMC meets periodically to review the safety and efficacy of the ongoing Phase 3 study. The data from all 928 enrolled patients were provided to the IDMC by the clinical research organization responsible for data management of this Phase 3 study. At the most recent IDMC meeting in October 2019 the IDMC reviewed “progression free and overall survival and limited demographi..."
10/15/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "AMENDED AND RESTATED ARTICLES OF INCORPORATION",
"BYLAWS",
"2019 NON-QUALIFIED STOCK OPTION PLAN",
"2019 STOCK COMPENSATION PLAN"
08/30/2019 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "EMPLOYMENT AGREEMENT GEERT KERSTEN",
"EMPLOYMENT AGREEMENT PATRICIA PRICHEP",
"EMPLOYMENT AGREEMENT EYAL TALOR"
08/16/2019 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "SECURITIES PURCHASE AGREEMENT"
05/20/2019 8-K Submission of Matters to a Vote of Security Holders
05/09/2019 8-K Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
Docs: "CEL-SCI CORPORATION RELEASES LETTER TO SHAREHOLDERS Vienna, VA, May 8, 2019 -- The following letter was sent by CEL-SCI Corporation to its shareholders: Dear CEL-SCI Shareholders: The first 4 months of this year have already been very positive for us. Our Phase 3 head and neck cancer study is continuing and we are moving forward with our Rheumatoid Arthritis product development. Since January 1, we have received about $9.6 million from the conversion of warrants to finance our ongoing projects. We believe the following developments with regard to the Multikine* Phase 3 trial have contributed to additional investments in our Company: 1. Length of Phase 3 study could be a sign of Multikine’s efficacy: We have not yet hit the primary endpoint of our 928 patient Phase 3 study with our investig..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy